Evidence map›Paper›PMID 30238584›Full record

Trial reportDermatologic therapy2019

A preliminary study of fractional CO

Xiang Wen, Michael R Hamblin, Yan Xian, Yong Li

Open access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Dermatologic therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Study on different fractional COLasers in medical science · 2025
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Xiang WenDepartment of Dermatology, West China Hospital of Sichuan University, Chengdu, Sichuan, China.ORCID 0000-0001-5572-715X
Michael R HamblinWellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts.
Yan XianDepartment of Dermatology, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
Yong LiDepartment of Dermatology, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
Sichuan University · CNHarvard University · US

Funding

Photodynamic Therapy of Localized InfectionsR01AI050875 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HAMBLIN, MICHAEL R · 2003 to 2017
$4.8M
Synergistic Photodynamic Therapy for Catherer-Associated Urinary Tract InfectionsR21AI121700 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HAMBLIN, MICHAEL R · 2016 to 2017
$462k
NIAID NIH HHS R01 AI050875NIAID NIH HHS R21 AI121700United States National Institute of Allergy and Infections Disease R01AI050875United States National Institute of Allergy and Infections Disease R21AI121700
6 · The paper itself

Abstract

Fractional CO

Indexed as

ChinaCombined Modality TherapyFemaleHumansImmunosuppressive AgentsLasers, ExcimerLasers, GasLow-Level Light TherapyMalePreliminary DataProspective StudiesSkin PigmentationTacrolimusTime FactorsTreatment OutcomeVitiligoImmunosuppressive AgentsTacrolimuslaser, therapy-topicalvitiligo

Identifiers

PMID30238584
PMCPMC6361687
OpenAlexW2891698489

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.